Finally, there is evidence that use of fluorine-18 fluciclovine and prostate-specific membrane antigen is not yet widespread.30 Going forward, the expected increased use of these imaging modalities, as well as the anticipated inclusion of prostate-specific membrane antigen-based positron emission tomographic imaging, will likely further be associated with the incidence rates of metastatic and locally advanced PCa. The gene discussed is FOLH1; the disease is posterior cortical atrophy.